Skip to content

Study · Not a test of the peptide alone · 1994

4 results

[Changes of immune and non-specific reactivity in patients with chronic suppurative obstructive bronchitis in comprehensive treatment with thymogen].

Litvinova NV, Eremeev VV, Abramova ZP, Kulikovskaia NV, Gergert VIa

Problemy tuberkuleza1 Jan 1994

PMID7984617 (opens in a new tab)PepBankPUB-07984617
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymogen (oglufanide).

  1. 01HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In chronic pyoobstructive bronchitis, multimodal treatment with thymogen increased E-rosette formation.

    In plain wordsIn patients with chronic bronchitis, combined treatment with thymogen increased E-rosette formation.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseE-rosette formation
    Study

    n = 33

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The use of thymogen in multi-modality treatment contributed to normalization of T-cell immunity (increases in E-rosette formation, responses of blast cell transformation to phytohemagglutinin, Tx/Tc ratio)
    1 context sentence
    Summary · context
    A total of 33 patients with chronic pyoobstructive bronchitis with immunological disorders (of T-cell and other links) and nonspecific responsiveness.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  2. 02HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In chronic pyoobstructive bronchitis, multimodal treatment with thymogen increased blast cell transformation responses to phytohemagglutinin.

    In plain wordsIn patients with chronic bronchitis, combined treatment with thymogen increased immune-cell responses to phytohemagglutinin.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseBlast cell transformation response to phytohemagglutinin
    Study

    n = 33

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The use of thymogen in multi-modality treatment contributed to normalization of T-cell immunity (increases in E-rosette formation, responses of blast cell transformation to phytohemagglutinin, Tx/Tc ratio)
    1 context sentence
    Summary · context
    A total of 33 patients with chronic pyoobstructive bronchitis with immunological disorders (of T-cell and other links) and nonspecific responsiveness.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  3. 03HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In chronic pyoobstructive bronchitis, multimodal treatment with thymogen increased the Tx/Tc ratio.

    In plain wordsIn patients with chronic bronchitis, combined treatment with thymogen increased the Tx/Tc ratio.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseTx/Tc ratio
    Study

    n = 33

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The use of thymogen in multi-modality treatment contributed to normalization of T-cell immunity (increases in E-rosette formation, responses of blast cell transformation to phytohemagglutinin, Tx/Tc ratio)
    1 context sentence
    Summary · context
    A total of 33 patients with chronic pyoobstructive bronchitis with immunological disorders (of T-cell and other links) and nonspecific responsiveness.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  4. 04HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In chronic pyoobstructive bronchitis, multimodal treatment with thymogen produced higher clinical efficacy.

    In plain wordsIn patients with chronic bronchitis, combined treatment with thymogen produced higher clinical efficacy.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseClinical efficacy
    Study

    n = 33

    Outcome group
    Overall treatment effect · Respiratory

    Source sentences

    Summary
    resulting in higher clinical efficacy.
    1 context sentence
    Summary · context
    A total of 33 patients with chronic pyoobstructive bronchitis with immunological disorders (of T-cell and other links) and nonspecific responsiveness.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.